Evidence map›Paper›PMID 40606996›Full record

ArticleFrontiers in oncology2025

Establishing preclinical models for clear cell sarcoma of soft tissue.

Bingbing X Li, Jake Piesner

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Choosing the right animal model for sarcoma research.Cellular and molecular life sciences : CMLS · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bingbing X LiProgram in Chemical Biology, Department of Chemical Physiology and Biochemistry, Oregon Health and Science University, Portland, OR, United States.
Jake PiesnerProgram in Chemical Biology, Department of Chemical Physiology and Biochemistry, Oregon Health and Science University, Portland, OR, United States.

Funding

Targeting EWS-ATF1 Fusion in Clear Cell Sarcoma of Soft TissueR01CA245964 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bingbing Li · 2022 to 2026
$2.2M
NCI NIH HHS R01 CA245964
6 · The paper itself

Abstract

Introduction: Clear cell sarcoma of soft tissue (CCSST) is a rare but aggressive soft tissue sarcoma driven by fusion proteins. The translocation of t(12;22) or t(2;22) leads to fusion formation between Ewing Sarcoma Breakpoint Region 1 ( Methods: We evaluated the transcriptional activity of seven EWSR1-ATF1 and one EWSR1-CREB fusion proteins using reporter assays. Migration and invasion assays were performed in CCSST cell lines. To model metastasis Results: We show that type 1, 2, 3 and 7 EWSR1-ATF1 fusions, as well as EWSR1-CREB are constitutively active while type 4, 5 and 6 are not. Among the four CCSST cell lines tested, only CCS292 showed invasion and migration potential, despite all lines harboring EWSR1-ATF1 fusions. CCS292 cells with firefly luciferase expression developed robust metastasis Conclusion: All the in-frame fusions are constitutively active. We developed both

Indexed as

ATF1CCSSTclear cell sarcoma of soft tissueCREB metastasisEWSR1invasion

Identifiers

PMID40606996
PMCPMC12213553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.